Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. NuVasive, Inc.
  6. News
  7. Summary
    NUVA   US6707041058

NUVASIVE, INC.

(NUVA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

NuVasive, Inc. Appoints Dale Wolf as Vice President, Manufacturing

08/16/2018 | 08:40am EST

NuVasive, Inc. announced the appointment of Dale Wolf as vice president, Manufacturing, who will oversee the company's West Carrollton, Ohio manufacturing facility. He will manage the 180,000 square foot manufacturing operations, and focus on optimizing output, advancing the insourcing strategy and streamlining processes, reporting directly to Steve Rozow, executive vice president, Global Process Transformation. With nearly two decades at General Electric (GE), Mr. Wolf has extensive experience in medical device manufacturing operations. Most recently, Mr. Wolf led GE Healthcare'sFlorence, South Carolina plant producing magnetic resonance imaging (MRI) components for the past four years.


© S&P Capital IQ 2018
All news about NUVASIVE, INC.
11/18NuVasive to Present at Piper Sandler 33rd Annual Virtual Healthcare Conference
PR
11/15Globus Medical in Talks About Possible NuVasive Takeover
MT
11/15Globus Medical Reportedly Eyes Acquisition of NuVasive
CI
11/15NuVasive Shares Halted, Globus Reportedly Makes Early Takeover Approach
MT
11/10Morgan Stanley Adjusts NuVasive's Price Target to $62 From $67, Maintains Equalweight R..
MT
11/10UBS Adjusts NuVasive PT to $54 From $59, Maintains Sell Rating
MT
11/10Needham Cuts NuVasive's Price Target to $64 From $73, Citing Q3 Miss; Buy Rating Kept
MT
11/09Credit Suisse 30th Annual Healthcare Conference
PU
11/09NuVasive Announces Third Quarter 2021 Financial Results - Form 8-K
PU
11/09NUVASIVE INC Management's Discussion and Analysis of Financial Condition and Results o..
AQ
More news
Analyst Recommendations on NUVASIVE, INC.
More recommendations
Financials (USD)
Sales 2021 1 136 M - -
Net income 2021 -15,5 M - -
Net Debt 2021 655 M - -
P/E ratio 2021 -125x
Yield 2021 -
Capitalization 2 473 M 2 473 M -
EV / Sales 2021 2,75x
EV / Sales 2022 2,47x
Nbr of Employees 2 700
Free-Float 88,0%
Chart NUVASIVE, INC.
Duration : Period :
NuVasive, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NUVASIVE, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 47,80 $
Average target price 66,60 $
Spread / Average Target 39,3%
EPS Revisions
Managers and Directors
J. Christopher Barry Chief Executive Officer & Director
Matthew K. Harbaugh Chief Financial Officer & Executive Vice President
Daniel J. Wolterman Chairman
Kyle Malone VP-Clinical, Medical & Regulatory Affairs
Aviva McPherron Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
NUVASIVE, INC.-15.04%2 473
ABBOTT LABORATORIES18.98%230 355
MEDTRONIC PLC-8.77%143 693
BECTON, DICKINSON AND COMPANY-3.42%69 336
HOYA CORPORATION28.35%59 756
DEXCOM, INC.40.51%50 350